Business
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results
NEWARK, Calif., March 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and year end 2019 financial results
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, Calif., March 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and year end 2019 financial results after the NASDAQ market closes on Tuesday, March 10, 2020. Protagonist management will host a year end update call at 4:30 p.m. EDT/1:30 p.m. PDT the same day.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast Information\nProtagonist executives will host a conference call at 4:30 p.m. EDT/1:30 p.m. PDT on Tuesday, March 10, 2020. To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and refer to conference ID number 5591627. A live and archived webcast of the call will also be accessible in the Investors section of the Company's website at www.protagonist-inc.com. A replay will be available on the company's website approximately two hours after the call and will remain available for 60 days.\nAbout Protagonist Therapeutics, Inc.\nProtagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three different assets in various stages of clinical development, and these were discovered internally through the use of its peptide technology platform. PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload and related blood disorders, including hereditary hemochromatosis and rare diseases such as beta-thalassemia and polycythemia vera. PTG-200 is an orally delivered, gut-restricted interleukin-23 receptor specific antagonist peptide in Phase 2 clinical development for the potential treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the clinical development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the potential treatment of inflammatory bowel disease, with a Phase 2 ulcerative colitis study expected to commence in the second quarter of 2020. Protagonist is headquartered in Newark, California. For further information, please visit www.protagon...